Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients

Antonio Silvani · Elena Lamperti · Paola Gaviani · Marica Eoli ·
Anna Fiumani · Andrea Salmaggi · Chiara Falcone · Graziella Filippini ·
Andrea Botturi · Amerigo Boiardi

Published online: 17 May 2008
© Springer Science+Business Media, LLC. 2008

Erratum to: J Neurooncol (2008) 87:143–151 DOI: [10.1007/s11060-007-9427-y](https://doi.org/10.1007/s11060-007-9427-y)

In addition to the errors specified in a previous erratum (J Neurooncol (2008) 87:153 / DOI [10.1007/s11060-008-9539-z](https://doi.org/10.1007/s11060-008-9539-z)), the following errors occur in the original publication:

Page 144, right column, section “Exclusion criteria”, end of 1st para: delete “(Fig. 1)”

Page 144, right column, section “Administration”, 1st line of 2nd para: “cheeked” should be “checked”

Page 146, left column, section “Surgery”, 3rd line: “About 33” should read “Thirty-three”

Page 146, right column, section “Chemotherapy”, 2nd line, “alkylatating” should read “alkylating”

Page 147, left column, section “Survival time”, last line of 2nd para: (95% CI, 16.9–22) should read (95% CI, 16.9–22)

Page 147, table 2, column Median PFS value for “Whole group of 54 recurrent glioblastoma patients”: 19.3 (13.7–24.4) should read 19.3 (14.1–24.4)

Page 148, table 3, column Median ST, value for “Whole group of 54 recurrent glioblastoma patients”: 28.7 (24.8–32.5) should read 28.7 (24.8–32.7)

Page 147, left column, section “Survival time”, fourth line of 1st para: (95% CI, 51.5–7.3) should read (95% CI, 51.5–77.3)

Page 147, right column, section “Toxicity”, 2nd line of 3rd para: percentage for 42 cycles “(26.5%)” should read “(28%)”

Page 147, right column, section “Toxicity”, 2nd line of 3rd para: percentage for grade 2 in 11 cycles “(6.85%)” should read “(7.3%)”

Page 147, right column, section “Toxicity”, 3rd line of 3rd para: percentage for grade 3–4 in 4 cycles “(2.5%)” should read “(2.6%)”

Page 147, right column, section “Toxicity”, 4th line of 3rd para: percentage for grade 4 in 4 “(2.25%)” should read “(2.6%)”

Page 147, right column, section “Toxicity”, 4th line of 3rd para: percentage for grade 4 in 2 “(1.25%)” should read “(1.3%)”

Page 148, table 3, column % Alive at 12 months, value for “II line chemotherapy: 31 patients treated at first recurrence-progression”: “36.1 (17.1–33.1)” should read “36.1 (17.1–55.1)”

Page 148, table 3, column Median ST, value for “III line chemotherapy: 23 patients treated at second recurrence-progression”: 26.6 (15.4–37.8) should read 26.6 (15.4–37.7)

Page 149, left column, 1st line of 6th para: “Fazen-Doerner” should read “Fazen-Dorner”

Page 149, right column, 1st line of 10th para “Beith et al. [46] showed that administration”: “PCZ” should read “PCB”

Page 148, right column, last sentence of the 3rd para “In recurrent GBM, no activity has been shown fro the taxanes, docetaxel, gemcitabine and EGFR tyrosine kinase inhibitors [23–27]”. Please include the two between the words taxanes, docetaxel, gemcitabine

The online version of the original article can be found under doi:
[10.1007/s11060-007-9427-y](https://doi.org/10.1007/s11060-007-9427-y).

A. Silvani (✉) · E. Lamperti · P. Gaviani · M. Eoli ·
A. Fiumani · A. Salmaggi · A. Botturi · A. Boiardi
Department of Neuro-oncology, Fondazione IRCCS Istituto
Neurologico “Carlo Besta”, Via Celoria, 11, Milan 20133, Italy
e-mail: silvani@istituto-besta.it

C. Falcone · G. Filippini
Neuro-epidemiology Unit, Fondazione IRCCS Istituto,
Neurologico “Carlo Besta”, Via Celoria, 11, Milan 20133, Italy